<DOC>
	<DOCNO>NCT00765583</DOCNO>
	<brief_summary>A total 75 subject enrol 36 month study . Subjects treat Restylane® side face ( nasolabial fold ) first visit , one side face month 4.5 side face month 9 . Both side face treated month 18 . The subject evaluate also evaluate treat doctor blind evaluator ( person know different side face treat ) . Side effect medication take study also record .</brief_summary>
	<brief_title>A Study Determine How Long Restylane® Will Last After Initial Treatment With 2 Different Re-treatment Schedules .</brief_title>
	<detailed_description>The study employ randomize , evaluator-blind design . One nasolabial fold randomly assign correct Restylane re-treated 4 ½ month . The opposite side treat Restylane re-treated 9 month . Both nasolabial fold re-treated 18 month . Each subject serve control , allow comparison outcome contralateral side . This multi-center U.S. trial plan enrollment 75 subject three center . The goal study enroll complete follow-up 60 evaluable subject . In order compensate early discontinuation , total least 75 subject recruit treat . After give write informed consent , potential study participant undergo screen evaluation initial treatment ( Visit 1 ) . The two nasolabial fold randomize treatment one side designate re-treatment Restylane 4 ½ month ; 9 month . At month 18 ( Visit 7 ) nasolabial fold re-treated . Follow-up visit schedule 36 month initial treatment touch-up .</detailed_description>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Males nonpregnant , nonbreast feeding female age 18 year old . Subjects seek augmentation therapy correction bilateral nasolabial fold . Subjects score 3 4 Severity Rating Scale . Subjects ability understand comply requirement trial . Subjects willing abstain exclusionary procedure ( e.g. , augmentation therapy , laser chemical resurfacing ; Botox® injection eye level ; facelift ) duration study . Subjects willing give write informed consent participate trial . Women childbearing potential must willing use acceptable form birth control study period . Active chronic skin disease , inflammation related condition , infection , psoriasis herpes zoster near nasolabial fold . Patients undergone procedure base active dermal response ( e.g . laser chemical peeling procedure ) , within 6 month prior study entry . Use facial tissue augment therapy aesthetic facial surgical therapy within nine ( 9 ) month prior study entry , e.g . injection form implantation tissue augment substance , Botox injection level eyebrow , facelift . Concomitant anticoagulant therapy , antiplatelet therapy , history bleeding disorder . Patients previously experience unanticipated adverse reaction treat hyaluronic acid base product . Any condition opinion investigator make patient unsuitable inclusion ( e.g. , patient likely avoid treatment , patient likely stay study six month , patient anticipate unreliable ) . Subjects cancerous precancerous lesion area treat . Use investigational drug device within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Wrinkles ( Nasolabial Folds )</keyword>
</DOC>